Novartis AG (NVSEF)
OTCMKTS · Delayed Price · Currency is USD
140.22
-6.87 (-4.67%)
At close: Jan 16, 2026
Novartis AG Revenue
Novartis AG had revenue of $14.36B in the quarter ending September 30, 2025, with 9.00% growth. This brings the company's revenue in the last twelve months to $56.37B, up 12.88% year-over-year. In the year 2024, Novartis AG had annual revenue of $51.72B with 10.85% growth.
Revenue (ttm)
56.37B
Revenue Growth
+12.88%
P/S Ratio
4.90
Revenue / Employee
742.88K
Employees
75,883
Market Cap
276.38B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 51.72B | 5.06B | 10.85% |
| Dec 31, 2023 | 46.66B | 3.20B | 7.36% |
| Dec 31, 2022 | 43.46B | -513.00M | -1.17% |
| Dec 31, 2021 | 43.97B | -5.92B | -11.87% |
| Dec 31, 2020 | 49.90B | 1.22B | 2.51% |
| Dec 31, 2019 | 48.68B | 2.58B | 5.59% |
| Dec 31, 2018 | 46.10B | 2.70B | 6.21% |
| Dec 31, 2017 | 43.40B | -6.03B | -12.20% |
| Dec 31, 2016 | 49.44B | -951.00M | -1.89% |
| Dec 31, 2015 | 50.39B | -3.25B | -6.05% |
| Dec 31, 2014 | 53.63B | 918.00M | 1.74% |
| Dec 31, 2013 | 52.72B | 745.00M | 1.43% |
| Dec 31, 2012 | 51.97B | -7.40B | -12.47% |
| Dec 31, 2011 | 59.38B | 7.81B | 15.15% |
| Dec 31, 2010 | 51.56B | 6.46B | 14.32% |
| Dec 31, 2009 | 45.10B | 2.52B | 5.92% |
| Dec 31, 2008 | 42.58B | 3.64B | 9.34% |
| Dec 31, 2007 | 38.95B | 3.84B | 10.94% |
| Dec 31, 2006 | 35.11B | 5.35B | 17.99% |
| Dec 31, 2005 | 29.75B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| American Oncology Network | 1.76B |
| Veradigm | 588.02M |
| Glass House Brands | 196.17M |
| Vaxart | 148.20M |
| Elite Pharmaceuticals | 122.89M |
| Zomedica | 29.45M |
| Silence Therapeutics | 25.83M |
| OpGen | 9.00M |
Novartis AG News
- 1 day ago - FDA Grants Novartis Breakthrough Therapy Status To Ianalumab For Sjögren's Disease - Nasdaq
- 1 day ago - Novartis (NVS) Gains FDA Breakthrough Status for Sjögren's Disease Therapy - GuruFocus
- 1 day ago - Novartis wins FDA breakthrough status for Sjögren’s disease therapy - Seeking Alpha
- 1 day ago - Novartis (NVS) Gains FDA Breakthrough Status for Sjogren's Disease Drug - GuruFocus
- 3 days ago - Generalized Myasthenia Gravis Market Outlook Shows Strong Momentum During the Forecast Period (2025–2034) Driven by Novel Immunotherapies | DelveInsight - Benzinga
- 4 days ago - Novartis CEO Dr. Vasant Narasimhan sits down with Jim Cramer - CNBC
- 4 days ago - Novartis (NVS) Secures License for Peptide-Based Radioligand Therapy - GuruFocus
- 4 days ago - Zonsen PepLib Biotech and Novartis Sign Worldwide License Agreement regarding Radioligand Therapy Asset - Business Wire